Literature DB >> 2998654

A study of DNA polymorphisms around the human apolipoprotein AI gene in hyperlipidaemic and normal individuals.

A M Kessling, B Horsthemke, S E Humphries.   

Abstract

We have used a 2.2 kb fragment of the human apolipoprotein AI (apo AI) gene to screen a number of unrelated individuals for common restriction fragment length polymorphisms (RFLPs) of the gene. As well as the previously reported SstI RFLP (allele frequencies in normolipidaemic individuals 0.94 and 0.06) we have detected RFLPs with the enzymes PstI and XmnI (allele frequencies in normolipidaemic individuals 0.88 and 0.12 for both polymorphisms). In the population studied, the RFLPs appear to be in linkage equilibrium and can be used in conjunction as a haplotype, with a PIC value (polymorphism information content) of 0.5. Significant differences in allele frequency were observed between subgroups of hyperlipidaemic patients and normolipidaemic controls. There is no strong population association in our patient group between any allele of the RFLPs studied and hypertriglyceridaemia.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998654     DOI: 10.1111/j.1399-0004.1985.tb00403.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  35 in total

1.  A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation.

Authors:  M R Nelson; S L Kardia; R E Ferrell; C F Sing
Journal:  Genome Res       Date:  2001-03       Impact factor: 9.043

2.  Extended haplotypes and linkage disequilibrium between 11 markers at the APOA1-C3-A4 gene cluster on chromosome 11.

Authors:  P Benlian; C Boileau; N Loux; D Pastier; J Masliah; M Coulon; M Nigou; A Ragab; J Guimard; J B Ruidavets
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

3.  Estimation of Hardy-Weinberg and pairwise disequilibrium in the apolipoprotein AI-CIII-AIV gene cluster.

Authors:  M B Haviland; A M Kessling; J Davignon; C F Sing
Journal:  Am J Hum Genet       Date:  1991-08       Impact factor: 11.025

4.  Association analysis of lipid levels and apolipoprotein restriction fragment length polymorphisms.

Authors:  O Myklebost; S Rogne; I Hjermann; B Olaisen; H Prydz
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

5.  Genetic evidence from two families that the apolipoprotein B gene is not involved in abetalipoproteinemia.

Authors:  P J Talmud; J K Lloyd; D P Muller; D R Collins; J Scott; S Humphries
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

6.  Apolipoprotein (apo) E genotypes by polymerase chain reaction and allele-specific oligonucleotide probes: no detectable linkage disequilibrium between apo E and apo CII.

Authors:  R S Houlston; C Snowden; F Green; K G Alberti; S E Humphries
Journal:  Hum Genet       Date:  1989-11       Impact factor: 4.132

7.  DNA polymorphism haplotypes of the human apolipoprotein APOA1-APOC3-APOA4 gene cluster.

Authors:  S E Antonarakis; P Oettgen; A Chakravarti; S L Halloran; R R Hudson; L Feisee; S K Karathanasis
Journal:  Hum Genet       Date:  1988-11       Impact factor: 4.132

8.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

9.  Characterization of a panel of somatic cell hybrids for subregional mapping along 11p and within band 11p13. Subdivision of the WAGR complex region.

Authors:  P Couillin; M Azoulay; I Henry; N Ravisé; M C Grisard; C Jeanpierre; F Barichard; P Metezeau; J J Candelier; W Lewis
Journal:  Hum Genet       Date:  1989-05       Impact factor: 4.132

10.  Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2. Induction of apo A-I mRNA with no change of apo B100 mRNA.

Authors:  A Kaptein; L Roodenburg; H M Princen
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.